JP2010501191A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501191A5
JP2010501191A5 JP2009525967A JP2009525967A JP2010501191A5 JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5 JP 2009525967 A JP2009525967 A JP 2009525967A JP 2009525967 A JP2009525967 A JP 2009525967A JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5
Authority
JP
Japan
Prior art keywords
fusion protein
component
nucleic acid
protein according
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525967A
Other languages
English (en)
Japanese (ja)
Other versions
JP5274464B2 (ja
JP2010501191A (ja
Filing date
Publication date
Priority claimed from EP06017891A external-priority patent/EP1894940A1/en
Application filed filed Critical
Publication of JP2010501191A publication Critical patent/JP2010501191A/ja
Publication of JP2010501191A5 publication Critical patent/JP2010501191A5/ja
Application granted granted Critical
Publication of JP5274464B2 publication Critical patent/JP5274464B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525967A 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質 Expired - Fee Related JP5274464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017891.0 2006-08-28
EP06017891A EP1894940A1 (en) 2006-08-28 2006-08-28 TNF superfamily fusion proteins
PCT/EP2007/007517 WO2008025516A2 (en) 2006-08-28 2007-08-28 Tnf superfamily fusion proteins

Publications (3)

Publication Number Publication Date
JP2010501191A JP2010501191A (ja) 2010-01-21
JP2010501191A5 true JP2010501191A5 (cg-RX-API-DMAC7.html) 2010-07-15
JP5274464B2 JP5274464B2 (ja) 2013-08-28

Family

ID=37836940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525967A Expired - Fee Related JP5274464B2 (ja) 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質

Country Status (8)

Country Link
US (2) US8147843B2 (cg-RX-API-DMAC7.html)
EP (2) EP1894940A1 (cg-RX-API-DMAC7.html)
JP (1) JP5274464B2 (cg-RX-API-DMAC7.html)
AT (1) ATE505481T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007291490A1 (cg-RX-API-DMAC7.html)
CA (2) CA2860945C (cg-RX-API-DMAC7.html)
DE (1) DE602007013920D1 (cg-RX-API-DMAC7.html)
WO (1) WO2008025516A2 (cg-RX-API-DMAC7.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
WO2010003766A2 (en) * 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
JP5674155B2 (ja) 2008-07-21 2015-02-25 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH Tnfsf一本鎖分子
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
JP6373836B2 (ja) 2012-07-26 2018-08-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
NO2776305T3 (cg-RX-API-DMAC7.html) 2014-04-23 2018-01-27
BR102014031185A8 (pt) * 2014-12-12 2021-05-04 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CA2999116A1 (en) 2015-09-23 2017-03-30 Apogenix Ag Anti-cd95l antibody
US20180312545A1 (en) * 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3565888A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11357841B2 (en) 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018209115A1 (en) 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2019032952A1 (en) 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
MX2020004967A (es) 2017-11-17 2020-08-27 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス,インコーポレイテッド 末梢血からの末梢血リンパ球(pbl)の拡大培養
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
JP2021509586A (ja) 2018-01-08 2021-04-01 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍抗原特異的t細胞について濃縮されたtil製品を生成するためのプロセス
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
EP4386080A3 (en) 2018-03-29 2024-12-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
AU2019375416A1 (en) 2018-11-05 2021-05-27 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive T-cells
ES3021682T3 (en) 2018-11-05 2025-05-27 Iovance Biotherapeutics Inc Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
JP2022506586A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
BR112021016875A2 (pt) 2019-03-01 2022-01-04 Iovance Biotherapeutics Inc Processo para expansão de linfócitos de sangue periférico
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球(til)の産生のためのプロセス及びそれを使用する方法
IL295990A (en) 2020-02-27 2022-11-01 Myst Therapeutics Llc Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス,インコーポレイテッド 改良された腫瘍反応性t細胞の選択
JP2023523855A (ja) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
US20240016918A1 (en) * 2020-08-24 2024-01-18 Sanofi Pasteur Inc. Vaccines against sars-cov-2 infections
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240299539A1 (en) 2020-12-17 2024-09-12 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス,インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス,インコーポレイテッド Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
CN117396520A (zh) * 2021-05-27 2024-01-12 北京安信怀德生物技术有限公司 包含两个trail三聚体的超trail分子
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
JP2024541911A (ja) 2021-10-27 2024-11-13 アイオバンス バイオセラピューティクス,インコーポレイテッド 患者特異的免疫療法のための細胞の製造を調整するためのシステム及び方法
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
EP4469066A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410525A1 (en) * 2000-05-26 2001-11-29 Mochida Pharmaceuticals Co., Ltd. Fas ligand-fused proteins

Similar Documents

Publication Publication Date Title
JP2010501191A5 (cg-RX-API-DMAC7.html)
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
JP7128246B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP6545759B2 (ja) アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
CN100385002C (zh) 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物
JP5274464B2 (ja) Tnfスーパーファミリー融合タンパク質
JP2021501581A5 (cg-RX-API-DMAC7.html)
HRP20150425T1 (hr) Tnf sf jednolanäśane molekule
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
JP6038816B2 (ja) 新規な超活性il−33断片およびその使用
WO2009149171A4 (en) Fgf21 mutants and uses thereof
CN104470944A (zh) 非天然共有白蛋白结合结构域
WO2010003766A2 (en) Multimeric tnf receptors
JP2018533947A5 (cg-RX-API-DMAC7.html)
CA2894219C (en) Novel interleukin-33 inhibitors
Yuan et al. Production of recombinant human interleukin-38 and its inhibitory effect on the expression of proinflammatory cytokines in THP-1 cells
JP5462623B2 (ja) Elr−cxcケモカインの高親和性アンタゴニスト
Goh et al. Structural and functional domains in human tumour necrosis factors
US7820622B2 (en) TNF antagonists
JP6320973B2 (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
Pyo et al. Expression and purification of a recombinant buforin derivative from Escherichia coli
JP2009536821A5 (cg-RX-API-DMAC7.html)
KR101955366B1 (ko) 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
JP5385611B2 (ja) Pf4とrantesとの相互作用に対するアンタゴニスト
CN102863538B (zh) 含蛋白转导域的融合多肽突变体及其制备方法